Altimmune Inc.’s recently made public that its Director Drutz David acquired Company’s shares for reported $862.0 on Aug 15. In the deal valued at $2.88 per share,300 shares were bought. As a result of this transaction, Drutz David now holds 29,785 shares worth roughly $ 78930.25.
Then, Eisenstadt Richard I bought 10,000 shares, generating $43,140 in total proceeds. Upon buying the shares at $4.31, the Chief Financial Officer now owns 22,010 shares.
Before that, Harris Matthew Scott bought 10,000 shares. Altimmune Inc. shares valued at $42,200 were divested by the Chief Medical Officer at a price of $4.22 per share. As a result of the transaction, Harris Matthew Scott now holds 33,311 shares, worth roughly $88274.15.
Goldman downgraded its Altimmune Inc. [ALT] rating to a Neutral from a a Buy in a research note published on Friday, March 22, 2023; the price target was decreased to $6 from $20. PT values the company’s stock at a premium of 55.83 to its Friday closing price.
Price Performance Review of ALT
On Friday, Altimmune Inc. [NASDAQ:ALT] saw its stock jump 4.74% to $2.65. On the same session, the stock had its day’s lowest price of $2.54, but rose to a high of $2.65. Over the last five days, the stock has gained 10.42%. Altimmune Inc. shares have fallen nearly -83.89% since the year began. Nevertheless, the stocks have fallen -88.00% over the past one year. While a 52-week high of $23.49 was reached on 01/13/23, a 52-week low of $2.34 was recorded on 08/28/23. SMA at 50 days reached $3.06, while 200 days put it at $7.54. A total of 0.92 million shares were traded, compared to the trading of 0.77 million shares in the previous session.
Levels Of Support And Resistance For ALT Stock
The 24-hour chart illustrates a support level at 2.58, which if violated will result in even more drops to 2.50. On the upside, there is a resistance level at 2.69. A further resistance level may holdings at 2.72. The Relative Strength Index (RSI) on the 14-day chart is 42.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.56%. Stochastics %K at 30.45% indicates the stock is a holding.
How much short interest is there in Altimmune Inc.?
A steep rise in short interest was recorded in Altimmune Inc. stocks on Aug 14, 2023, dropping by -1.57 million shares to a total of 5.78 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 7.35 million shares. There was a decline of -27.16%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 11.07% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.41.
Altimmune Inc. [ALT] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 3,361,432 shares, or roughly 6.82% of the outstanding ALT shares. In other words, the investor’s shares have risen by 2,049,696 from its previous 13-F filing of 1311736.0. Additionally, TIAA-CREF Investment Management L increased 0.76% of its stake after which the total value it holdings stand at $10,899,019, while The Vanguard Group, Inc. added 31.46% of its stake to hold $10.81 million in the firm. At present, Laurion Capital Management LP is holding 1,839,604 shares valued at $6.09 million. Avidity Partners Management LP owned 1,174,100 shares of the company at the time of its most recent 13F filing, worth $3.89 million.
According to FactSet, Altimmune Inc.’s share price will average $19.43 in the next year, based on opinions of analysts polled by the firm. This is up nearly 492.89 percent from its previous closing price of $2.53. Analysts expect Altimmune Inc. stock to reach the higher price of $35.00, while the lowest price estimate is $6.00. However, 7 analysts have rated ALT stock as a Buy in their predictions for 2023.